Therapeutic Effects of Water-Soluble Sparganium Stoloniferum extract on Hyperglucagonemia in Diabetes

Presentation Number: SAT 581
Date of Presentation: April 1st, 2017

Jean Kim*1, Yoon Hee Cho2 and Eun Jig Lee3
1Yonsei University College of Medicine and Brain Korea 21 PLUS, 2Yonsei University, 3Yonsei University College of Medicine, Seoul, Korea, Republic of (South)

Abstract

Therapeutic effects of water-soluble Sparganium stoloniferum extract on hyperglucagonemia in diabetes

Objective

Rhizome of Sparganium has been used in oriental medicine in order to improve various physical functions. The aim of this study is to investigate the effects of water-soluble Sparganium stoloniferum Extract (SSE) on hyperglucagonemia in regulation of glucagon release in diabetic animal model and control of related signaling molecules.

Methods

For the in vitro study, we examined intracellular Ca2+ influx, cAMP activity, glucagon secretion and related signaling pathway in αTC1-9 cells. For the in vivo study, forty C57BL/6 male mice were divided into three groups and treated with Streptozotocin (75 mg/kg, 3days) and Sparganium stoloniferum Extract (100 mg/kg, 7days) : Normal control (n=10); STZ (n=15); STZ+SSE (n=15). To determine the protein expression of the pancreas and liver, tissue was immediately frozen in liquid nitrogen or fixed with 4% paraformaldehyde for staining.

Results

SSE reduced the intracellular Ca2+ influx, cAMP activity, and glucagon secretion in αTC1-9 cells stimulated with high glucose (26mM). Also, SSE inhibited the CREB and PKA phosphorylation induced by cAMP activity. In the diabetic mice fed the SSE, circulating glucagon secretion was reduced while insulin level was increased and finally, blood glucose level was reduced. During fasting, the activation of gluconeogenic genes by CREB phosphorylation was reduced in the diabetic mice fed the SSE by decreasing expression of coactivator PGC-1 in liver.

Conclusion

In this study, we studied the therapeutic effects of water-soluble Sparganium stoloniferum extract on hyperglucagonemia in diabetes.

 

Nothing to Disclose: JK, YHC, EJL